NewAmsterdam Pharma Options Point to Major Bet on PREVAIL Trial Outcome

A large and complex options trade in NewAmsterdam Pharma (NASDAQ:NAMS) on Tuesday suggests a major investor is positioning for significant stock price movement tied to the company's pivotal PREVAIL clinical trial. The activity involved closing a profitable bearish position and establishing a new, multi-leg strategy focused on the first quarter of 2027.

Anatomy of the Trade

Analysis of market data from September 8 shows a single entity likely executed the series of trades, which involved a total of 16,000 contracts across four specific options, according to Investing.com. The transaction appears to be a "roll," where an existing position is closed and a new one is opened simultaneously.

The trade consisted of two main parts:

• Position Closed: An investor sold to close 4,000 contracts of the September 18, 2026, $30 strike puts. With NAMS trading around $25.03 at the time, this position was deeply in-the-money, allowing the trader to lock in profits.
• New Position Opened: The same investor simultaneously bought a combination of options expiring on February 19, 2027: 4,000 of the $30 calls, 4,000 of the $40 calls, and 4,000 of the $30 puts.

Positioning for a Binary Event

Ad

The February 2027 expiration date is critical, as it aligns directly with the expected interim data readout from NewAmsterdam's PREVAIL trial for its drug candidate, obicetrapib. This trial is widely seen as a make-or-break catalyst for the company.

The structure of the new position is effectively a long strangle with a bullish tilt. By purchasing both calls (betting on a price increase) and puts (hedging against a price decrease), the investor is betting on a large move in either direction. The heavier weighting on the call side, with strikes at $30 and an aggressive $40, indicates a stronger conviction for a positive trial outcome.

Market Signals and Context

The trade was executed as the stock's three-month implied volatility fell sharply, a phenomenon known as "volatility crush" that often follows a major news event. This allowed the investor to establish the new position at a relatively lower cost.

However, market data also shows a rising "skew," meaning the cost of downside puts is increasing relative to upside calls. This suggests that while one major player is making a structured bullish bet, the broader market remains nervous and is still pricing in significant potential downside risk for NewAmsterdam Pharma.